ORIGINAL RESEARCH article
Front. Oncol.
Sec. Breast Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1568550
Clinical study of 99m Tc-Rituximab combined with dyes double tracing for axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer
Provisionally accepted
- Department of Breast Surgery, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background and Objective:Whether SLNB after neoadjuvant chemotherapy (NAC)for breast cancer is an alternative to ALND remains controversial.In this study,the results of SLNB performed with 99mTc-Rituximab combined with dyes were analyzed,and the application value of the double-tracing method of 99m Tc-Rituximab combined with dyes in SLNB after breast cancer NAC was evaluated,the feasibility of SLNB after NAC and the clinical application of the novel tracer 99mTc-Rituximab and its IMLN was discussed.Methods:A retrospective analysis of 106 breast cancer patients who underwent post-NAC SLNB from August 2019 to August 2023 at Fujian Provincial Hospital,where SLNB was performed using 99mTc-Rituximab combined with dye imaging or dye imaging alone.The detection rate, sensitivity,false-negative rate, accuracy and the detection rate of IMLN biopsy were compared between the two tracing methods. Results:70 cases were included in the dual-tracer group,with a detection rate of 97.14% (68/70), an average number of detected SLNs of (6.06±5.29) ,a sensitivity of 92.86% (26/28), a false negative rate of 7.14% (2/28), and an accuracy of 97.14% (68/70). 36 cases were included in the single-tracer group, with a detection rate of 66.67%(24/36),an average number of detected SLNs of(3.17±3.073),a sensitivity of 54.55%(11/22), a false negative rate of 45.45% (10/22), and an accuracy of 72.22%(26/36).There were significant differences in the detection rate and the average number of detected SLNs between the two groups (detection rate:P=0.004;detection number: P=0.038), but there were no significant differences in the sensitivity, accuracy,and false negative rate (P>0.05). A total of 70 patients were examined for IMLN biopsy with dual tracer,and 22 patients were detected with an imaging rate of 31.42%(22/70),and a detection rate of 72.72% (16/22). Conclusions:For patients with breast cancer,the dual-tracer method combining radionuclide and dye for SNLB after NAC can improve the detection rate of sentinel lymph nodes and reduce the false-negative rate.In the long term,the quality of life of patients can be helped to improve by this approach.Compared with other tracers,99mTc-Rituximab can improve the detection rate of internal mammary lymph nodes,with the characteristics of rapid clearance of injection site,less secondary lymph node visualization,and hypoallergenicity,which can be used as an ideal tracer for further research.
Keywords: breast cancer, neoadjuvant chemotherapy (NAC), Sentinel lymph node biopsy (SLNB), 99mTc-Rituximab, Axillary lymph node dissection (ALND)
Received: 30 Jan 2025; Accepted: 14 Jul 2025.
Copyright: © 2025 Zhuang, Lin, Qiu, Chen, Zeng, Lin, Zhang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Mengbo Lin, Department of Breast Surgery, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian Province, China
Hui Zhang, Department of Breast Surgery, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.